Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014677 · ClinicalTrials.gov registry record · Phase 2
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00014677 is a Phase 2 study that has completed, run by Neurocrine Biosciences.
The verdict
NCT00014677, a Phase 2 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: NBI-3001 may be able to locate cancer cells and stop them from growing. This may be an effective treatment for glioblastoma multiforme. PURPOSE: Randomized phase II trial to compare different regimens of NBI-3001 followed by surgery to remove the tumor in treating patients who have glioblastoma multiforme.
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL interleukin-4 PE38KDEL cytotoxin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014677
The ClinicalTrials.gov registry entry for NCT00014677 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which conventional surgery is the first listed.
NCT00014677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014677 about?
NCT00014677 is a clinical study titled "NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme". RATIONALE: NBI-3001 may be able to locate cancer cells and stop them from growing. This may be an effective treatment for glioblastoma multiforme. PURPOSE: Randomized phase II trial to compare different regimens of NBI-3001 followed by surgery to remove the tumor in treating patients who have gliob...
What is the current status of trial NCT00014677?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00014677?
The interventions under investigation include: conventional surgery (PROCEDURE), interleukin-4 PE38KDEL cytotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00014677?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.